Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

Abstract

BACKGROUND AT-101 is an inhibitor of Bcl-2 family proteins including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. In vivo and in vitro studies have exhibited broad activity of AT-101, including synergy with docetaxel in non-small cell lung cancer tumor models. METHODS We conducted a prospective, randomized (1:1), double-blind, placebo-controlled phase 2 study… (More)
DOI: 10.1097/JTO.0b013e31820a0ea6

4 Figures and Tables

Topics

  • Presentations referencing similar topics